AstraZeneca’s Post

Our Chief Medical Officer, Tadaaki Taniguchi, spoke with MedCity News about how Astellas is driving forward a broad, investigational pipeline focused on new therapeutic targets.    Tadaaki touches on our approach to developing and delivering novel oncology therapies for a range of cancer types. He also covers how innovation partnerships are expediting progress in areas like #GeneTherapy.     Read the full interview here: https://lnkd.in/g8QDdD25 #ChangingTomorrow  

🔹 The utmost importance of timely and equal patient access to innovative oncology drugs across Europe was the focus of the presentation by Teodora Kolarova, INCA Executive Director, at the The Cancer Drug Development Forum (CDDF) workshop on “Clinical Research in Central and Eastern Europe: New Approaches for the Next Level of Development”.  This multi-stakeholder workshop brought together a diverse group of stakeholders to facilitate dialogue and collaboration on improving clinical research in CEE.  👉 Teodora Kolarova voiced out the cancer patient perspective and emphasized that further efforts should be placed to explore the potential role of adaptive pathways and joint HTA-EMA procedures in assuring timely and equal access to oncology medicines in the European Union.  ☑ Read more: https://lnkd.in/dzUrAA3a #LetsTalkAboutNETs #NeuroendocrineCancer #ClinicalTrials 

Breaking Barriers in Esophageal Cancer Treatment! Esophageal cancer (EC) remains a critical challenge, but innovative therapies are shaping the future. With marketed and pipeline drugs under assessment, the landscape is evolving with clinical insights, pricing strategies, and commercial catalysts. From leading marketed products to Phase Transition Success Rates (PTSR) and Likelihood of Approval (LoA)—this report delivers actionable insights for strategic decision-making. Whether you're looking at M&A deals or licensing strategies, staying ahead is key! #EsophagealCancer #PharmaInnovation #DrugPipeline #ClinicalTrials #BusinessStrategy Explore more here: https://lnkd.in/dgjyhhT9  

Unlocking new vaccine adjuvants and delivery systems has been a game-changer in advancing oncology drug development. The research and developments in this field are promising and offer hope for more effective cancer therapies. Discover more about these exciting breakthroughs in the new article by Pharma insights! Click here to read: https://ow.ly/qbpm30sEqsh #CrodaPharma #EmpoweringBiologicsDelivery #PharmaInsights

In oncology trials, every second, every penny, and every test is crucial. So how can you ensure none are wasted? 🤔 By using a Data Monitoring Committee (DMC) to review your oncology clinical trial data, you can identify ineffective and unsafe treatments early, so valuable time, money, and resources can be better allocated to more promising options.💡 Read more on the critical role of DMCs in oncology research: https://hubs.ly/Q02M9wCj0 #Oncology #ClinicalResearch #DataMonitoring #PatientSafety #ClinicalTrials #OncologyResearch #DMC #CytelInsights

Partnerships remain a key driver of the progress being made in #CellAndGeneTherapy to deliver breakthrough oncology treatments. Our EVP, Head of Corporate Strategy, Peter Sandor and Poseida Therapeutics’ CEO, Kristin Yarema, Ph.D., sat down with In Vivo to discuss how aligning on a shared vision early in the dealmaking process, combining expertise, and empowering teams to act quickly can accelerate progress for patients. At Astellas, we actively seek partnerships with ambitious companies like Poseida Therapeutics who share our deep commitment to science and patient care. To learn more on how we are working together to advance allogeneic CAR-T cell therapies to potentially transform the lives of cancer patients, read on here: https://lnkd.in/dUh8bcH3 *You may need to register to read the article. #ScienceFirstForPatients #ChangingTomorrow

Unlocking new vaccine adjuvants and delivery systems has been a game-changer in advancing oncology drug development. The research and developments in this field are promising and offer hope for more effective cancer therapies. Discover more about these exciting breakthroughs in the new article by Pharma insights! Click here to read: https://ow.ly/BrqG30sEpyC #CrodaPharma #EmpoweringBiologicsDelivery #PharmaInsights

The FDA, and more specifically, the Oncology division [https://lnkd.in/g7jub_s3], has been deeply involved in disseminating information, holding webinars, and providing continued guidance [https://lnkd.in/gBcNA5vB.] on optimizing doses for the treatment of cancer patients. Please find a super helpful final guidance document. Along with reaching out to get assistance from experts like Nathan Teuscher, the approaches suggested in this guidance can be useful not just to those developing therapies in oncology but for other indications as well.

While the FDA’s Project Frontrunner guidance aims to expand access to a wider patient population, it also represents a major paradigm shift in regulatory guidance. When moving oncology drug development into earlier stages of disease, oncology drug developers will be expected to significantly adapt their trial design. Learn how partnering with IQVIA can help you navigate the changing landscape and bring novel therapies to cancer patients faster. https://bit.ly/4a5uQjp #oncology #drugdevelopment

Unlocking new vaccine adjuvants and delivery systems has been a game-changer in advancing oncology drug development. The research and developments in this field are promising and offer hope for more effective cancer therapies. Discover more about these exciting breakthroughs in the new article by Pharma insights! Click here to read: https://ow.ly/K1Gm30sEo93 #CrodaPharma #EmpoweringBiologicsDelivery #PharmaInsights